You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,888,469


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,888,469
Title:Post-translation modification and clostridial neurotoxins
Abstract: The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain.
Inventor(s): Steward; Lance E. (Irvine, CA), Fernandez-Salas; Ester (Fullerton, CA), Spanoyannis; Athena (Ashburn, VA), Aoki; K. Roger (Coto de Caza, CA), Lin; Wei-Jen (Cerritos, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:11/624,146
Patent Claims:1. A botulinum neurotoxin comprising a structural modification, wherein the structural modification comprises at least one additional N-glycosylation site, wherein the botulinum neurotoxin can interfere with the functions of a neuron, and wherein the additional N-glycosylation site increases biological persistence of the botulinum neurotoxin relative to a naturally-occurring botulinum neurotoxin of the same serotype without the additional N-glycosylation site.

2. The botulinum toxin of claim 1, wherein the additional N-glycosylation site is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26 and any combination thereof.

3. The botulinum neurotoxin of claim 1, wherein the botulinum neurotoxin is selected from the group consisting of a botulinum toxin type A, a botulinum toxin type B, a botulinum toxin type C1, a botulinum toxin type D, a botulinum toxin type E, a botulinum toxin type F and a botulinum toxin type G.

4. The botulinum neurotoxin of claim 3, wherein the botulinum neurotoxin is a botulinum toxin type A.

5. The botulinum neurotoxin of claim 3, wherein the botulinum neurotoxin is a botulinum toxin type C1.

6. The botulinum neurotoxin of claim 3, wherein the botulinum neurotoxin is a botulinum toxin type E.

7. A botulinum neurotoxin comprising a proteolytic domain from the light chain of a clostridial neurotoxin and at least one additional N-glycosylation site, wherein the additional N-glycosylation site increases biological persistence of the modified botulinum neurotoxin relative to a naturally-occurring botulinum neurotoxin of the same serotype without the additional N-glycosylation site.

8. The botulinum toxin of claim 7, wherein the additional N-glycosylation site is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26 and any combination thereof.

9. The botulinum neurotoxin of claim 7, wherein the botulinum neurotoxin further comprises a H.sub.N fragment from the heavy chain of a Clostridial neurotoxin.

10. The botulinum neurotoxin of claim 7, wherein the botulinum neurotoxin further comprises a H.sub.C fragment derived from the heavy chain of a Clostridial neurotoxin.

11. The botulinum neurotoxin of claim 7, wherein the botulinum neurotoxin further comprises a H.sub.N fragment from the heavy chain of a Clostridial neurotoxin and a H.sub.C fragment derived from the heavy chain of a Clostridial neurotoxin.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.